Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Price Target at $65.00

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given a consensus recommendation of “Buy” by the seven research firms that are covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $65.00.

A number of equities analysts recently commented on the company. BTIG Research initiated coverage on Arcturus Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $41.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Friday, February 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th.

Arcturus Therapeutics Stock Down 2.2 %

NASDAQ:ARCT opened at $17.32 on Thursday. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00. The stock’s fifty day moving average is $16.97 and its two-hundred day moving average is $18.86. The stock has a market capitalization of $469.20 million, a price-to-earnings ratio of -7.80 and a beta of 2.62.

Institutional Investors Weigh In On Arcturus Therapeutics

Large investors have recently modified their holdings of the company. nVerses Capital LLC acquired a new position in shares of Arcturus Therapeutics during the third quarter worth $42,000. Virtus ETF Advisers LLC boosted its position in shares of Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 1,132 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Arcturus Therapeutics in the 4th quarter valued at about $71,000. China Universal Asset Management Co. Ltd. raised its position in shares of Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 2,038 shares in the last quarter. Finally, National Bank of Canada FI lifted its stake in Arcturus Therapeutics by 639.6% during the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 4,784 shares during the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.